T0	Participants 51 83	acute myeloid leukemia patients.
T1	Participants 547 697	newly diagnosed AML patients from 2 large study groups (the German AML Cooperative Group and the Dutch-Belgian Hematology Oncology Cooperative group).
T2	Participants 1251 1284	261 patients from a third cohort.